Living Donor Navigator Program Tele-health for Kidney Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Alabama at Birmingham, Birmingham, AL
Kidney Diseases
Living Donor Navigator Program - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

We hypothesize that expansion of the Living Donor Navigator (LDN) program to include tele-health delivery will overcome geographic disparities in access and facilitate sustained increases in living donation. We will utilize an individually randomized group trial (IRGT) design with delayed intervention initiation to compare the effectiveness of tele-health LDN model to standard of care.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Within 3 months of condition

Month 3
Number Live Donor Screenings
Number of Live Donor Approvals

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Living Donor Navigator Program Tele-health
1 of 2
Living Donor Navigator Program In-person
1 of 2
Active Control

440 Total Participants · 2 Treatment Groups

Primary Treatment: Living Donor Navigator Program Tele-health · No Placebo Group · N/A

Living Donor Navigator Program Tele-health
Behavioral
ActiveComparator Group · 1 Intervention: Living Donor Navigator Program · Intervention Types: Behavioral
Living Donor Navigator Program In-person
Behavioral
ActiveComparator Group · 1 Intervention: Living Donor Navigator Program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 3 months of condition

Trial Background

Prof. Jayme E Locke, Professor of Surgery
Principal Investigator
University of Alabama at Birmingham
Closest Location: University of Alabama at Birmingham · Birmingham, AL
Photo of university of alabama at birmingham  1Photo of university of alabama at birmingham  2Photo of university of alabama at birmingham  3
1991First Recorded Clinical Trial
21 TrialsResearching Kidney Diseases
1066 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have end-stage kidney disease (ESKD) and are ≥ 18 years old.
If there is an individual willing to donate, but the candidate is unwilling to consider this option or this particular individual, the candidate is eligible for the study and may still benefit from identification of new donors or increased comfort accepting donation from others.
You are fluent in English or deaf and hard of hearing.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.